The Lancet
Oncology by Elizabeth Gourd
NEWS| VOLUME
20, ISSUE 10, PE562, OCTOBER 01, 2019
Patients with previously
treated HER2-positive relapsed or metastatic breast cancer have significantly
better outcomes when treated with pyrotinib plus capecitabine than with
lapatinib plus capecitabine, according to a recent study.
